Other
VRD
VRD is an intervention with 3 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
OTHER
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
2(67%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_2
1
33%
Ph phase_1
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Active, not recruiting1
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
2
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
N/A1 (33.3%)
Trials by Status
active_not_recruiting133%
completed133%
recruiting133%
Recent Activity
2 active trials
Showing 3 of 3
completednot_applicable
The Effect of Virtual Reality Distraction on Pain During Colonoscopy
NCT07496333
active_not_recruitingphase_2
A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma
NCT05860036
recruitingphase_1
Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
NCT04025450
Clinical Trials (3)
Showing 3 of 3 trials
NCT07496333Not Applicable
The Effect of Virtual Reality Distraction on Pain During Colonoscopy
NCT05860036Phase 2
A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma
NCT04025450Phase 1
Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients
All 3 trials loaded
Drug Details
- Intervention Type
- OTHER
- Total Trials
- 3